Real-world evidence of nivolumab for non-small-cell lung cancer in a developing country

无容量 医学 中止 四分位间距 内科学 肺癌 肿瘤科 置信区间 回顾性队列研究 癌症 外科 免疫疗法
作者
Mauricio Luján,Mauricio Lema,Beatriz Preciado,Camila Lema,Jorge Egurrola,Andrés F. Cardona,Diego González,William Mantilla,Luís Pino,Gustavo Bueno Rojas,Diego Hernán Arias Gómez,Isabel Munévar,Raimundo Manneh,Ray Manneh Kopp,José Lobatón,Esteban Calle,Mariana Borras Osorio,Iván Triana,P.A. Londoño,Sandra Aruachán
出处
期刊:Journal of Investigative Medicine [SAGE Publishing]
卷期号:71 (5): 502-510 被引量:1
标识
DOI:10.1177/10815589221147897
摘要

Nivolumab is a human programmed death receptor-1 blocking antibody, used as treatment option in patients with advanced non-small-cell lung cancer (NSCLC). We assessed the nivolumab efficacy in terms of survival and response to treatment as second-line (2L) or third-line (3L) therapy in patients with advanced NSCLC. This is a multicentric observational study. Data of patients with advanced NSCLC who received nivolumab as 2L or 3L treatment were analyzed retrospectively. Information regarding patient demographics and clinical backgrounds, treatment patterns from diagnosis to post-nivolumab treatment, effectiveness, and safety of nivolumab treatment were collected. The outcomes evaluated were overall survival (OS), progression-free survival (PFS), and objective response rate (ORR) to treatment. OS and PFS were estimated with the Kaplan-Meier method and the differences were evaluated through the log-rank test. Data of 178 patients were included. The median follow-up was 26.8 months (interquartile range (IQR): 20.3-40.4). Nivolumab was commonly used as a 2L treatment (77.5%). The outcomes in this setting (2L) were as follows: ORR was 21.0%, and the median PFS and OS were 5.5 months (95% confidence interval (CI): 4.5-6.5) and 12.4 months (95% CI: 10.8-14.0), respectively. In 3L, the ORR with nivolumab was 15.0%, the median PFS and OS were 4.1 months (95% CI: 3.1-5.1) and 10.1 months (95% CI: 9.4-10.6), respectively. Three patients (1.7%) required discontinuation due to toxicity. Nivolumab effectiveness and safety in this scenario was consistent with that reported by previous trials and other real-world data.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
深情的乐萱完成签到,获得积分10
1秒前
小金鱼166完成签到,获得积分10
5秒前
小金鱼8569完成签到,获得积分10
10秒前
13秒前
小金鱼8569完成签到,获得积分10
14秒前
DL_zhai完成签到,获得积分10
14秒前
16秒前
18秒前
xiaojinyu195完成签到,获得积分10
18秒前
18秒前
DMUXLW完成签到,获得积分10
20秒前
21秒前
xiaojinyu131完成签到,获得积分10
22秒前
24秒前
bean完成签到,获得积分10
26秒前
26秒前
萌萌2完成签到,获得积分10
26秒前
31秒前
萌萌1完成签到,获得积分10
31秒前
scenery0510完成签到,获得积分0
36秒前
43秒前
43秒前
44秒前
46秒前
英吉利25发布了新的文献求助10
47秒前
CC完成签到,获得积分10
47秒前
48秒前
50秒前
50秒前
52秒前
hhhh777完成签到 ,获得积分10
53秒前
54秒前
54秒前
54秒前
英吉利25发布了新的文献求助10
54秒前
54秒前
果子完成签到 ,获得积分10
56秒前
56秒前
57秒前
抗体药物偶联完成签到,获得积分10
58秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190320
求助须知:如何正确求助?哪些是违规求助? 9577417
关于积分的说明 21852481
捐赠科研通 7788909
什么是DOI,文献DOI怎么找? 3436315
关于科研通互助平台的介绍 2560144
邀请新用户注册赠送积分活动 2482975